Feeds:
Posts
Comments

Archive for August, 2009

TODAY’S NEWS

AstraZeneca’s experimental drug may bring serious competition to Plavix - AstraZeneca‘s new pill Brilinta for preventing heart attacks works better than Plavix, the world’s second biggest selling drug, without increasing the amount of life-threatening bleeding, researchers said on Sundaymore

B-I‘s new drug Praxada poised to finally provide an alternative to warfarin – Patients at risk of stroke due to an erratic heartbeat should soon have a viable alternative to 50-year-old warfarin, after a new pill from Boehringer Ingelheim beat expectations in a major clinical studymore Plus, new B-I drug for COPD is looking promising.

Encouraging results for Angiomax in cardiac mortality/survival study – The Medicines Company today announced the publication of one-year results from the landmark HORIZONS-AMI Trial. The trial showed that patients who had suffered the most severe form of heart attack and received angioplasty were significantly less likely to suffer cardiac death and had significantly better overall survival if treated with Angiomax (bivalirudin) compared with those treated with heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI)more

FDA to Allos: not so sure about your lymphoma data – Food and Drug Administration reviewers, in a summary prepared for an advisory panel, said their two issues with Allos’ application were “the clinical significance of tumor response and duration of response” as well as “whether the benefit:risk ratio is favorable” for Folotynmore

RECOMMENDED

Technology. Learning Management Systems. On-line assessment. eMarketing. Social Media. If you’re looking for expertise, and/or for vendor connections in the technology sphere, Impactiviti can help. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

Couldn’t stop myself from including a link to this press release – can you discover what in the world the product being discussed is for? Neither can I…

JUST FOR FUN

Turn up your speakers, sit back for a minute or two, and just enjoy this remarkable video. Rain.

On a personal note: Next week one of my sons joins the Marines. Some thoughts from a proud Dad.

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Takeda to move forward with new alogliptin study – Takeda Pharmaceutical Co says it is all set to start an additional clinical trial demanded by US regulators on alogliptin, its investigational type 2 diabetes drug. The Japanese drugmaker noted that the US Food and Drug Administration has agreed to the study design for a cardiovascular outcomes trial, titled EXAMINE for alogliptin, a selective dipeptidyl peptidase IV inhibitor (DPP-4) inhibitor also known as SYR-322. The study will involve 5,400 type 2 diabetes patients at around 1,000 facilities in the USA, Europe and Asiamore

Genzyme leukemia drug study: hard to interpret - “The lack of a randomized study combined with the heterogeneous patient population regarding AML prognostic factors makes interpretation of the study results difficult.” Food and Drug Administration staff said in an analysis prepared for the panel, which meets Tuesdaymore

Smoker’s lung treatment: coming soon from Forest and Nycomed? – An experimental once-daily tablet from Nycomed and Forest Laboratories improves lung function in people with “smoker’s lung” and may be a useful add-on to conventional inhaled drugs, experts said on Friday. Privately owned Swiss drugmaker Nycomed, which is working towards a multibillion-dollar flotation, hopes Daxas will reach the market in 2010 and believes it has blockbuster potentialmore

Pharmas that got hurt by debt shenanigans, including BMS and Teva. And, a rash of drug heists.

RECOMMENDED

Social Media monitoring. It’s one thing to launch a social media app. It’s another to actively monitor comments, discussions, and manage forums. If you’re looking at this need, the Impactiviti Partner Network can help. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

Younger folks just don’t want to take their cholesterol meds.

JUST FOR FUN

A Danger sign you don’t want to see…
———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

Did you know you can get Impactiviti Daily (Top Pharma News) direct to your Inbox each morning? Just click here to subscribe!

TODAY’S NEWS

Lots on J&J today – Elimination of the comprehensive care business unit; warnings of allergic reactions to its HIV drug Intelence; FDA finger-wagging for “misleading” advertising of athlete’s foot cream; no further development of once-per-month Risperdal Consta.

Up-and-coming new drugs looking encouraging: eye drug Xibrom QD from Ista, and lupus drug from UCB/Immunomedics.

BMS‘ RA drug Orencia gets an expanded label.

RECOMMENDED

Talent Management. Employee Assessments. We can help. The Impactiviti Partner Network has what you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

The Golden Rule? Or the Gold-in Rule? What’s at the heart of your business? A guest post on the leading healthcare blog KevinMD. AND – Pharma Exec’s listing of the Top 50 Pharma Companies (2008)

JUST FOR FUN

Talent. Sometimes these TV shows uncover gems. Check out this guy from X-Factor:


———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

What should be the foundation of a pharma company’s business ethics – the Golden Rule or the Gold-in Rule? That’s the subject of my guest post on the healthcare blog KevinMD. And, lest any think I have unbalanced views, here’s a counter-balancing thought (for the record).

Read Full Post »

Did you know you can get Impactiviti Daily (Top Pharma News) direct to your Inbox each morning? Just click here to subscribe!

TODAY’S NEWS

Amylin to be led by former Novartis exec – Amylin Pharmaceuticals has taken another step forward in its long & storied history. The company has announced that former Novartis executive Paulo Costa will become its new chairmanmore

An interesting lawsuit: individual suing Celgene for blockbuster drug idea – In 1996, Beth Jacobson was watching her husband, a 35-year-old cardiologist, die from the blood cancer multiple myelomamore

Gene variation impacts 1/3 of Plavix patients? – A common gene variation explains why many people are not helped by the widely prescribed blood thinner Plavix, U.S. researchers said on Tuesday in a study confirming earlier research and paving the way for tests to screen patients before they get the drugmore

From the rumor mill – Glaxo eyeing Human Genome Sciences? And, is B-I cutting a major percentage of its sales force in the U.S.? (can anyone confirm or deny with facts?)

RECOMMENDED

Corporate HR workshops – Sexual Harassment. Compliance. Communications. Ethics. Diversity. The Impactiviti Partner Network has what you need. Contact me (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

Are placebos getting more effective? What’s going on here? - From 2001 to 2006, the percentage of new products cut from development after Phase II clinical trials, when drugs are first tested against placebo, rose by 20 percent. The failure rate in more extensive Phase III trials increased by 11 percent, mainly due to surprisingly poor showings against placebomore

JUST FOR FUN

Who’s got the better colors? An eye-popping series of 3 photos you’ll enjoy!

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

Did you know you can get Impactiviti Daily (Top Pharma News) direct to your Inbox each morning? Just click here to subscribe!

TODAY’S NEWS

P&G’s drug unit to be snapped up, by… – Warner Chilcott Ltd, a specialty drug maker, is acquiring Procter & Gamble Co‘s prescription drug business for about $3 billion, two sources familiar with the matter said on Sunday…more

FDA approves infantile spasm drug (from Lundbeck) – The Food and Drug Administration on Friday approved the first drug for treating infantile spasms, a rare and devastating disease that wracks infants with hundreds of spasms every day, interferes with neurological development and kills as many as 20% of victims…more

J&J‘s experimental anti-epilepsy drug – FDA says, no thanks.

From the rumor mill – Teva eyeing Shire?

RECOMMENDED

Training Strategy – One of the areas for which I provide “traditional” consulting is training strategy – working with you to look at the big picture and develop comprehensive blueprints for more effective training. I can also work with your department on RFP development, technology platforms, vendor selection and management strategies, and project management processes. Contact me (stevew at impactiviti dot com, or phone at 973-947-7429) for more information!

PLUS

Some great thoughts on Leading, from Seth Godin’s blog.

JUST FOR FUN

Erupting volcanoes on Earth, as seen from space. Very cool.

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Why Pharma wants Obamacare. Thought provoking analysis from Forbes.

I like the headline: No Non-sinister Deed goes Unpunished. An interesting story about lobbying, healthcare reform, and The Medicines Company.

Takeda re-acquires Actos marketing rights in Canada.

RECOMMENDED

Negotiations Training – For Reps, Account Managers, and even up to the C-Suite: Impactiviti’s partner network includes some great suppliers for training on Negotiations Skills. Contact me (stevew at impactiviti dot com, or phone at 973-947-7429) for  vendor recommendations on this or any other training need!

PLUS

ePharma Review: Novartis‘ just launched YouTube channel. I consider it a good toe in the water, even if it is one-way communication…

JUST FOR FUN

It’s a cloudy day here in North Jersey. So, here are some amazing pictures of very unusual cloud formations. Enjoy!

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.

Join 29 other followers